Hudson Bay Capital Management LP Raises Stake in Arbutus Biopharma Co. (NASDAQ:ABUS)

Hudson Bay Capital Management LP increased its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,112,500 shares of the biopharmaceutical company's stock after acquiring an additional 82,500 shares during the quarter. Hudson Bay Capital Management LP owned about 0.59% of Arbutus Biopharma worth $3,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of ABUS. Rangeley Capital LLC bought a new position in shares of Arbutus Biopharma in the 4th quarter worth about $4,771,000. JPMorgan Chase & Co. increased its stake in shares of Arbutus Biopharma by 900.4% in the 4th quarter. JPMorgan Chase & Co. now owns 896,258 shares of the biopharmaceutical company's stock worth $2,931,000 after acquiring an additional 806,672 shares in the last quarter. Two Seas Capital LP increased its stake in shares of Arbutus Biopharma by 4.2% in the 4th quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company's stock worth $28,583,000 after acquiring an additional 353,568 shares in the last quarter. BlackBarn Capital Partners LP increased its stake in shares of Arbutus Biopharma by 13.1% in the 4th quarter. BlackBarn Capital Partners LP now owns 2,341,871 shares of the biopharmaceutical company's stock worth $7,658,000 after acquiring an additional 270,971 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of Arbutus Biopharma by 466.3% in the 3rd quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company's stock worth $1,047,000 after acquiring an additional 223,995 shares in the last quarter. 43.79% of the stock is currently owned by institutional investors.

Arbutus Biopharma Trading Down 1.3%

NASDAQ:ABUS traded down $0.04 on Friday, reaching $3.08. 1,052,601 shares of the stock traded hands, compared to its average volume of 1,006,604. The company has a market capitalization of $589.90 million, a price-to-earnings ratio of -7.16 and a beta of 1.50. Arbutus Biopharma Co. has a 12 month low of $2.71 and a 12 month high of $4.73. The company's fifty day simple moving average is $3.28 and its 200 day simple moving average is $3.37.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.04). The company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $2.54 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. Equities analysts anticipate that Arbutus Biopharma Co. will post -0.39 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on ABUS shares. StockNews.com upgraded shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, March 29th. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Finally, Chardan Capital restated a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.